secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-18T12:33:17+00:00
Accession:  0001178913-26-002761
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026
--------------------------------------------------------------------------------

- Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.
- Cash and equivalents $2.4M at Mar 31, 2026, down from $6.0M at Dec 31, 2025; post-quarter capital raises of $1.0M from warrant inducement.
- Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer; CTA submitted to Germany.
- Phase 2/3 trial initiation remains on track for Q2 2026 with safety run-in of ~18 patients, then randomized cohort of ~166.
- Company believes post-quarter equity transactions restored Nasdaq compliance with $2.5M minimum shareholders' equity requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/0001178913-26-002761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/zk2635360.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer